What is Zacks Research’s Forecast for TBPH Q1 Earnings?

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Equities researchers at Zacks Research reduced their Q1 2025 earnings estimates for Theravance Biopharma in a research report issued on Wednesday, March 19th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings of ($0.43) per share for the quarter, down from their prior estimate of ($0.36). The consensus estimate for Theravance Biopharma’s current full-year earnings is ($1.09) per share. Zacks Research also issued estimates for Theravance Biopharma’s Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.29) EPS, Q1 2026 earnings at ($0.50) EPS, Q2 2026 earnings at ($0.50) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at $0.19 EPS, FY2026 earnings at ($1.13) EPS and FY2027 earnings at ($0.96) EPS.

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Theravance Biopharma in a research note on Tuesday, February 25th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, Theravance Biopharma presently has an average rating of “Hold” and a consensus target price of $13.75.

Theravance Biopharma Trading Down 0.9 %

Shares of TBPH opened at $9.31 on Monday. The firm has a market cap of $460.58 million, a P/E ratio of -9.22 and a beta of 0.15. The stock’s 50 day moving average is $9.36 and its two-hundred day moving average is $9.08. Theravance Biopharma has a 12 month low of $7.44 and a 12 month high of $10.90.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.26). The business had revenue of $18.75 million for the quarter, compared to analyst estimates of $29.90 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%.

Insider Activity

In other news, SVP Rhonda Farnum sold 4,000 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the transaction, the senior vice president now directly owns 309,565 shares of the company’s stock, valued at approximately $2,786,085. This trade represents a 1.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in TBPH. Aquatic Capital Management LLC purchased a new stake in shares of Theravance Biopharma in the fourth quarter valued at about $25,000. Quantbot Technologies LP acquired a new stake in Theravance Biopharma during the 3rd quarter worth approximately $60,000. KLP Kapitalforvaltning AS acquired a new position in shares of Theravance Biopharma in the fourth quarter worth $69,000. Teacher Retirement System of Texas purchased a new stake in shares of Theravance Biopharma during the fourth quarter worth $103,000. Finally, ClearAlpha Technologies LP purchased a new position in Theravance Biopharma in the fourth quarter valued at $109,000. 99.10% of the stock is currently owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.